Table 2 KEGG enrichment results of the hub targets among olanzapine, schizophrenia, bipolar disorder, and agitation.
ID | Term | Count | Gene | P-value |
|---|---|---|---|---|
hsa04151 | PI3K-Akt signaling pathway | 13 | GSK3B, BDNF, FN1, IGF1, NGF, FGF2, NFKB1, INS, IL6, CREB1, BCL2, AKT1, TP53 | 9.22E-13 |
hsa05215 | Prostate cancer | 9 | GSK3B, CREB1, BCL2, CTNNB1, AKT1, IGF1, TP53, NFKB1, INS | 1.35E-11 |
hsa04010 | MAPK signaling pathway | 11 | BDNF, IL1B, AKT1, FOS, IGF1, NGF, TNF, TP53, FGF2, NFKB1, INS | 1.69E-10 |
hsa05135 | Yersinia infection | 9 | IL10, GSK3B, IL6, IL1B, FN1, AKT1, FOS, TNF, NFKB1 | 2.23E-10 |
hsa05417 | Lipid and atherosclerosis | 10 | GSK3B, IL6, IL1B, BCL2, AKT1, PPARG, FOS, TNF, TP53, NFKB1 | 2.44E-10 |
hsa04932 | Non-alcoholic fatty liver disease | 9 | GSK3B, IL6, IL1B, AKT1, PPARG, FOS, TNF, NFKB1, INS | 6.01E-10 |
hsa05200 | Pathways in cancer | 12 | GSK3B, IL6, BCL2, FN1, CTNNB1, AKT1, PPARG, FOS, IGF1, TP53, FGF2, NFKB1 | 2.20E-09 |
hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 9 | GSK3B, IL6, CREB1, CTNNB1, AKT1, FOS, TP53, FGF2, NFKB1 | 3.59E-09 |
hsa05162 | Measles | 8 | GSK3B, IL6, IL1B, BCL2, AKT1, FOS, TP53, NFKB1 | 1.02E-08 |
hsa05418 | Fluid shear stress and atherosclerosis | 8 | IL1B, BCL2, CTNNB1, AKT1, FOS, TNF, TP53, NFKB1 | 1.07E-08 |
